Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.92
NVGN's Cash to Debt is ranked higher than
67% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. NVGN: 0.92 )
NVGN' s 10-Year Cash to Debt Range
Min: 0.92   Max: No Debt
Current: 0.92

Equity to Asset 0.32
NVGN's Equity to Asset is ranked higher than
51% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. NVGN: 0.32 )
NVGN' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.86
Current: 0.32

0.32
0.86
F-Score: 2
Z-Score: -43.75
M-Score: 0.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -7650.57
NVGN's Operating margin (%) is ranked lower than
55% of the 861 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.67 vs. NVGN: -7650.57 )
NVGN' s 10-Year Operating margin (%) Range
Min: -7650.57   Max: -31.89
Current: -7650.57

-7650.57
-31.89
Net-margin (%) -8583.91
NVGN's Net-margin (%) is ranked lower than
55% of the 861 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. NVGN: -8583.91 )
NVGN' s 10-Year Net-margin (%) Range
Min: -8583.91   Max: 53.43
Current: -8583.91

-8583.91
53.43
ROE (%) -216.46
NVGN's ROE (%) is ranked lower than
54% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. NVGN: -216.46 )
NVGN' s 10-Year ROE (%) Range
Min: -269.02   Max: 33.98
Current: -216.46

-269.02
33.98
ROA (%) -116.38
NVGN's ROA (%) is ranked lower than
55% of the 914 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. NVGN: -116.38 )
NVGN' s 10-Year ROA (%) Range
Min: -143.49   Max: 12.06
Current: -116.38

-143.49
12.06
ROC (Joel Greenblatt) (%) -12250.31
NVGN's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 908 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.66 vs. NVGN: -12250.31 )
NVGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18600   Max: -69.26
Current: -12250.31

-18600
-69.26
Revenue Growth (3Y)(%) -100.00
NVGN's Revenue Growth (3Y)(%) is ranked lower than
54% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. NVGN: -100.00 )
NVGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 2
Current: -100

-100
2
EBITDA Growth (3Y)(%) -28.60
NVGN's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NVGN: -28.60 )
NVGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59.5   Max: 31.5
Current: -28.6

-59.5
31.5
EPS Growth (3Y)(%) -14.50
NVGN's EPS Growth (3Y)(%) is ranked higher than
63% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. NVGN: -14.50 )
NVGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.5   Max: 24.1
Current: -14.5

-62.5
24.1
» NVGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

NVGN Guru Trades in Q4 2012

Jim Simons 48,940 sh (+4.93%)
Ronald Muhlenkamp 18,184 sh (-49.15%)
» More
Q1 2013

NVGN Guru Trades in Q1 2013

Ronald Muhlenkamp Sold Out
Jim Simons 44,940 sh (-8.17%)
» More
Q2 2013

NVGN Guru Trades in Q2 2013

Jim Simons 15,240 sh (-66.09%)
» More
Q3 2013

NVGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2013-03-31 Sold Out 0.03%$1.84 - $9.05 $ 2.4-37%0
Ronald Muhlenkamp 2012-12-31 Reduce -49.15%0.01%$1.5 - $10.24 $ 2.4-52%18184
Ronald Muhlenkamp 2012-06-30 New Buy0.02%$1.95 - $2.5 $ 2.46%35757
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.50
NVGN's P/B is ranked higher than
52% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. NVGN: 12.50 )
NVGN' s 10-Year P/B Range
Min: 0.95   Max: 13.11
Current: 12.5

0.95
13.11
EV-to-EBIT -2.93
NVGN's EV-to-EBIT is ranked higher than
64% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.22 vs. NVGN: -2.93 )
NVGN' s 10-Year EV-to-EBIT Range
Min: -44   Max: 0.2
Current: -2.93

-44
0.2
Current Ratio 0.81
NVGN's Current Ratio is ranked lower than
54% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. NVGN: 0.81 )
NVGN' s 10-Year Current Ratio Range
Min: 0.81   Max: 9.78
Current: 0.81

0.81
9.78
Quick Ratio 0.81
NVGN's Quick Ratio is ranked higher than
50% of the 892 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. NVGN: 0.81 )
NVGN' s 10-Year Quick Ratio Range
Min: 0.81   Max: 8.68
Current: 0.81

0.81
8.68

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -32.70
NVGN's Earnings Yield (Greenblatt) is ranked lower than
52% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. NVGN: -32.70 )
NVGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 629.7   Max: 16900.9
Current: -32.7

629.7
16900.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NRT.Australia, NV9.Germany, NV9B.Germany,
Novogen Ltd
» More Articles for NVGN

Headlines

Articles On GuruFocus.com
comment on NVGN Mar 06 2013 

More From Other Websites
Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private... Dec 19 2014
Novogen Raises A$4.1m In Private Placement to US Institutions Dec 17 2014
Novogen Announces Breakthrough Discovery in the Treatment of Melanoma Dec 16 2014
Novogen Shares Skyrocket 120% Following Drug News Dec 16 2014
Novogen Provides Update On Progress Of Cantrixil Into The Clinic Dec 15 2014
Graham Kelly PhD, CEO & Chairman attended the Rodman & Renshaw 16th Annual Global Investment... Sep 29 2014
ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer Sep 29 2014
Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference Sep 03 2014
Novogen Announces Results of General Meeting of Shareholders Aug 13 2014
Novogen Receives Funding Support To Commence Studies In Muscular Dystrophy Aug 12 2014
Novogen And CanTx Appoint Contract Manufacturers To Produce Clinical Batches Of Cantrixil™ Jul 25 2014
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant... Jun 17 2014
5 Reasons Why We Believe Novogen Is Poised For Success Jun 05 2014
Novogen rises 14.7% May 27 2014
Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer May 27 2014
Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for... May 04 2014
Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative... May 02 2014
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo Mar 18 2014
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York Mar 12 2014
Novogen Selected to Present at Cavendish Global Health Impact Forum Mar 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK